Blood Transfusion/*mortality Combined Modality Therapy Cystectomy/*mortality Humans *Perioperative Care Prognosis Survival Rate Urinary Bladder Neoplasms/pathology/*therapy Bladder cancer Blood transfusion Cystectomy Meta-analysis Oncology Systematic review

Cystectomy/*methods Humans *Margins of Excision Survival Rate Ureter/*surgery Urinary Bladder Neoplasms/mortality/*surgery Bladder cancer Cancer de vessie Cystectomie Cystectomy Examen extemporané Frozen section Recoupes urétérales Ureteral margin

Radical cystectomy bladder preservation distant metastasis rate (DMR) muscular invasive bladder cancer (MIBC) survival rate form (available at https://dx.doi.org/10.21037/tau-21-564). The authors have no conflicts of interest to declare.

Carcinoma Transitional Cell/*mortality/*pathology Humans Survival Rate Urinary Bladder Neoplasms/*mortality/*pathology carcinoma histology pathology survival transitional cell urinary bladder neoplasms

Carcinoma Transitional Cell/*classification/*genetics/mortality Humans Predictive Value of Tests Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*classification/*genetics/mortality Bladder cancer Molecular classification Molecular subtype Prognosis Progression Urothelial carcinoma

Chemotherapy Adjuvant *Combined Modality Therapy Cystectomy Female Humans Middle Aged Muscles Neoadjuvant Therapy *Neoplasm Invasiveness Organ Sparing Treatments Patient Selection Quality of Life Salvage Therapy Survival Rate *Urinary Bladder Neoplasms/therapy

Chemotherapy Adjuvant *Cystectomy/methods Humans Neoadjuvant Therapy Smoking/*adverse effects Survival Rate Treatment Outcome Urinary Bladder Neoplasms/drug therapy/*mortality/*surgery cigarette smoking cystectomy recurrence survival urinary bladder neoplasms

*Biomarkers Tumor Carcinoma Transitional Cell/*genetics/mortality/pathology *DNA Methylation Humans Neoplasm Invasiveness Prognosis Risk Assessment Survival Rate Urinary Bladder Neoplasms/*genetics/mortality/pathology Biomarkers Dna High-risk non–muscle-invasive bladder cancer Methylation Prognostic markers Systematic review molecular markers

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy Adjuvant *Cystectomy/methods Humans Neoadjuvant Therapy Neoplasm Invasiveness Survival Rate Urinary Bladder Neoplasms/*drug therapy/mortality/pathology/*surgery Muscle-invasive bladder cancer Neoadjuvant chemotherapy Overall survival Radical cystectomy

*Cystectomy/methods Humans Postoperative Complications/*epidemiology Prognosis Survival Rate Urinary Bladder Neoplasms/*mortality/*surgery Bladder cancer clinical markers morbidity mortality radical cystectomy survival

Carcinoma Transitional Cell/diagnosis/epidemiology/*therapy Child Combined Modality Therapy *Disease Management Disease Progression Global Health Humans Incidence Risk Factors Survival Rate/trends Urinary Bladder/*pathology Urinary Bladder Neoplasms/diagnosis/epidemiology/*therapy Management Pediatric Surveillance Transurethral resection Urothelial cell carcinoma

Cystectomy/methods/*mortality Humans Lymph Node Excision/methods/*mortality Lymph Nodes/surgery Lymphatic Metastasis Pelvis/pathology Postoperative Complications/etiology Prognosis Randomized Controlled Trials as Topic Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*mortality/pathology/*surgery

Databases Factual Disease-Free Survival Humans Lymphocytes/*cytology/immunology Neoplasm Metastasis Neutrophils/*cytology/immunology Odds Ratio Prognosis Proportional Hazards Models Risk Assessment Survival Rate Urinary Bladder Neoplasms/immunology/mortality/*pathology Urologic Neoplasms/immunology/mortality/*pathology Bladder cancer Metastatic unresectable urothelial carcinoma Neutrophil-Lymphocyte ratio Unresectable urothelial carcinoma

Adjuvants Immunologic/*therapeutic use Administration Intravesical BCG Vaccine/*therapeutic use Carcinoma Transitional Cell/pathology/*therapy Cystoscopy Female Humans Male Multivariate Analysis Muscle Smooth/*pathology Neoplasm Invasiveness Neoplasm Recurrence Local/*epidemiology Proportional Hazards Models Sex Factors Survival Rate Urinary Bladder Neoplasms/pathology/*therapy *Urologic Surgical Procedures Bladder cancer Gender differences Local recurrence Meta-analysis Transurethral resection of bladder tumor

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Cisplatin/administration & dosage Deoxycytidine/administration & dosage/analogs & derivatives Doxorubicin/administration & dosage Humans Methotrexate/administration & dosage Muscle Neoplasms/*drug therapy/pathology Neoplasm Invasiveness Prognosis Survival Rate Urinary Bladder Neoplasms/*drug therapy/pathology Vinblastine/administration & dosage Gemcitabine Bladder cancer and cisplatin chemotherapy doxorubicin/adriamycin gemcitabine and cisplatin methotrexate vinblastine

Adenocarcinoma/epidemiology/*pathology/surgery Cystectomy/*methods Digital Rectal Examination Humans Incidental Findings Male Neoplasm Recurrence Local/pathology Prognosis Prostate/pathology Prostate-Specific Antigen Prostatectomy/*methods Prostatic Neoplasms/epidemiology/*pathology/surgery Survival Rate Urinary Bladder Neoplasms/*surgery bladder neoplasms cystectomy prostatectomy prostatic neoplasms

Humans Neoplasm Grading Neoplasm Invasiveness Neoplasm Recurrence Local/*pathology Neoplasm Staging Neoplasm Residual *Reoperation Risk Factors Survival Rate Urinary Bladder/pathology Urinary Bladder Neoplasms/*pathology/*surgery Bladder Cancer Detrusor Muscle Progression Re-resection Recurrence Upstaging

Antineoplastic Agents/*therapeutic use Carcinoma Transitional Cell/pathology/*therapy Chemotherapy Adjuvant Cystectomy Cystoscopy Humans Lymph Node Excision Muscle Smooth/*pathology *Neoadjuvant Therapy Neoplasm Invasiveness *Organ Sparing Treatments Progression-Free Survival Proportional Hazards Models *Radiotherapy Adjuvant Survival Rate Urinary Bladder Neoplasms/pathology/*therapy Bladder preserving Cancer Muscle invasive Radical cystectomy Trimodal

Aged Aged 80 and over Chemoradiotherapy/*mortality/*statistics & numerical data Combined Modality Therapy Cystectomy/*mortality/*statistics & numerical data Disease-Free Survival Female Humans Male Middle Aged Neoplasm Invasiveness Postoperative Complications/mortality/prevention & control Prevalence Radiation Injuries/mortality/prevention & control Risk Factors Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*mortality/*therapy

Administration Intravesical Antineoplastic Combined Chemotherapy Protocols/*administration & dosage Carcinoma Transitional Cell/mortality/*pathology/*therapy Disease Progression Doxorubicin/administration & dosage/analogs & derivatives Epirubicin/administration & dosage Humans Mitomycin/administration & dosage Neoplasm Recurrence Local/*prevention & control Neoplasm Staging Randomized Controlled Trials as Topic Risk Factors Survival Rate Thiotepa/administration & dosage Time Factors Urinary Bladder Neoplasms/mortality/*pathology/*therapy Chemotherapy Meta-analysis Non–muscle-invasive bladder cancer Single instillation Systematic review